Skip to content

Evaluation of Nucleotide-Binding Oligomerization Domain-Containing Protein (NOD) 1 and NOD 2

Evaluation of Nucleotide-Binding Oligomerization Domain-Containing Protein (NOD) 1 and NOD 2 in Different Periodontal Conditions

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07160894
Enrollment
75
Registered
2025-09-08
Start date
2025-09-15
Completion date
2026-07-20
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Diseases Inflammation

Keywords

periodontal disease NOD

Brief summary

The host immune response to microorganisms is primarily recognized by pattern recognition receptors (PRRs), including toll-like receptors and nucleotide-binding oligomeric domain (NOD) receptors (NLRs). The aim of this study was to examine the relationship between periodontal disease and NOD in serum and saliva samples.

Detailed description

Healthy participants (n:25), gingivitis (n:25) patients and stage III, grade B periodontitis (n:25) patients enrolled for this study. Clinical periodontal parameters and salivary flow rate were noted. Serum and saliva samples were collected to measure NOD1, NOD2, IL-10 and IL-6 levels.

Interventions

Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 5 mL of blood samples were collected by qualified staff from each participant.Saliva and serum were then stored at -80 °C until analysis.

Sponsors

Medipol University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Saliva and serum of periodontitis patients collected for analyzing NOD1, NOD2, IL-10 and IL-6

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* systemically healthy * clinical diagnosis of periodontal health * clinical diagnosis of periodontitis * clinical diagnosis of gingivitis

Exclusion criteria

* • history of regular use of systemic antibiotics anti-inflammatory, or antioxidant drugs (previous 3 months) * nonsurgical periodontal treatment (previous 6 months) * surgical periodontal treatment (previous 12 months) * presence of\<10 teeth * current medications affecting gingival health (calcium channel blockers, phenytoin, cyclosporine, and hormone replacement therapy) * diabetes * diagnosis of rheumatoid arthritis * pregnancy * lactating * smoking * excessive alcohol consumption.

Design outcomes

Primary

MeasureTime frameDescription
Pocket probing depth6 monthsMeasurement of the depth of a sulcus or periodontal pocket determined by measuring distance from a gingival margin to the base of the sulcus or pocket with a calibrated periodontal probe.
Clinical attachment level6 monthsClinical attachment level (or loss, CAL) is a more accurate indicator of the periodontal support around a tooth than probing depth alone. CAL is measured from a fixed point on the tooth that does not change, the CEJ. To calculate CAL, two measurements are needed: distance from the gingival margin to the CEJ and probing depth. In recession: probing depth (+) gingival margin to the CEJ (add). In tissue overgrowth: probing depth (-) gingival margin to the CEJ (subtract)
Bleeding on probing6 monthsReferring to bleeding that is induced by gentle manipulation of the tissue at the depth of the gingival sulcus, or interface between the gingiva and a tooth.

Secondary

MeasureTime frameDescription
Saliva and serum samples processing and analyses1 monthSaliva and serum samples obtained for each patient were used for cytokine analysis. Prepared samples were analyzed for NOD1, NOD2, IL-10 and IL-6 using commercial ELISA kits

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026